BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. FXYD4, T cell receptor signaling pathway, HIV infection, Neuron, Nosology, Bleomycin)
Bookmark Forward

QuickView for parC;jsessionid=ECC51C810F3D6B4326F31276183814AE;jsessionid=49430B1327AA0F9E6BCEB84B15B37A65;jsessionid=2CDD2478015636747A2C0E802376E40C;jsessionid=ED6A742EE0A00D7CAB637D9D08CF9E16;jsessionid=CF6E6A1B6539E5805B3CF1F335F73434;jsessionid=D95143867337B2CD14C1CF2B3A371216;jsessionid=5C81BAC0DBC3970249868EA14D3BA23B;jsessionid=3F9DA9768009B1F7AAEFF27FAF692741;jsessionid=41C8861F9516166746CBC43682CD022B (gene)


Body Atlas

Most Correlated Tissues

  1. Testes
  2. Transverse colon
  3. Rectum colon
  4. Ascending colon
  5. Putamen
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Varicella-zoster virus infection
  2. Placental insufficiency
  3. Pneumocystosis
  4. Infestation by Sarcoptes scabiei var canis
  5. Obsessive-compulsive disorder
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. isochlorogenic acid
  2. triflusal
  3. zaprinast
  4. Solanine
  5. trimethobenzamide
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. KANSL3
  2. NR2C2
  3. RPS2
  4. POU2AF1
  5. EN2
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. A proteomics approach for the identification of cullin-9 (CUL9) related signaling pathways in induce…
  2. Characterization of a Cul9-Parkin double knockout mouse model for Parkinson's disease.
  3. Cytoplasmic E3 ubiquitin ligase CUL9 controls cell proliferation, senescence, apoptosis and genome i…
  4. Killing the Killer: PARC/CUL9 promotes cell survival by destroying cytochrome C.
  5. CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrit…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

There were no clinical trials for parC;jsessionid=ECC51C810F3D6B4326F31276183814AE;jsessionid=49430B1327AA0F9E6BCEB84B15B37A65;jsessionid=2CDD2478015636747A2C0E802376E40C;jsessionid=ED6A742EE0A00D7CAB637D9D08CF9E16;jsessionid=CF6E6A1B6539E5805B3CF1F335F73434;jsessionid=D95143867337B2CD14C1CF2B3A371216;jsessionid=5C81BAC0DBC3970249868EA14D3BA23B;jsessionid=3F9DA9768009B1F7AAEFF27FAF692741;jsessionid=41C8861F9516166746CBC43682CD022B
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.